Author Topic: (Abst.) Tysabri's effect on disease progression in SPMS  (Read 116 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Tysabri's effect on disease progression in SPMS
« on: March 14, 2018, 06:28:54 am »
From The Lancet Neurology (March 12, 2018).This study was funded by Biogen. It shows that Tysabri didn't change the EDSS score for persons with SPMS but did improve arm functioning somewhat, using the 9-hole peg test:


Quote
No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT [9-hole peg test] progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab.



http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30069-3/fulltext
« Last Edit: March 14, 2018, 06:30:47 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics